Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Outset Medical, Inc.'s SEC filings document operating results, product and service revenue, gross margin, cash resources, and guidance for its dialysis technology business. Recent Form 8-K reports furnish earnings releases for the Tablo Hemodialysis System business and disclose material events such as FDA 510(k) clearance for the next-generation Tablo platform.
Proxy materials and current reports also cover governance and compensation matters, including board composition, director independence, committee appointments, executive compensation tables, pay-versus-performance disclosures, and equity awards. The filing record ties these disclosures to Outset’s capital structure, Nasdaq-listed common stock, and medical-device regulatory environment.
Omnicell stockholder Marc Nash filed a notice of proposed sale under Rule 144. He plans to sell 980 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/21/2026, with an aggregate market value of $4,876.11. The shares are listed on NASDAQ, and the issuer had 18,153,090 shares outstanding at the time stated.
The securities to be sold were acquired on 01/17/2026 via settlement of 14,839 vested restricted stock units as equity compensation for services rendered. Over the prior three months, Nash sold additional common shares, including 247 shares for $1,136.20, 108 shares for $461.16, and 5,375 shares for $27,520.00. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about the issuer.
OM insider John Brottem has filed a Form 144 indicating an intention to sell 1,180 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ around 01/21/2026. The aggregate market value of these shares is listed as $5,913.82, compared with 18,153,090 shares of common stock outstanding. The shares to be sold stem from equity compensation: on 01/17/2026, Brottem acquired 17,997 shares via settlement of vested restricted stock units as payment for services.
Over the prior three months, Brottem has sold additional OM common stock, including 388 shares for $1,784.80 on 11/17/2025, 244 shares for $956.48 on 01/07/2026, and 9,314 shares for $47,682.76 on 01/20/2026. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
A holder of common stock in OM has filed a notice of proposed sale under Rule 144. The filer plans to sell 5,375 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 27,520.00, on or about 01/20/2026 on the NASDAQ market. The seller reports that 18,153,090 shares of this class of common stock are outstanding.
The securities to be sold were acquired on 01/17/2026 via settlement of vested restricted stock units granted by the issuer as equity compensation for services rendered, totaling 14,839 shares. Over the prior three months, the same person sold smaller amounts of common stock, including 247 shares on 11/17/2025 for gross proceeds of 1,136.20 and 108 shares on 01/07/2026 for gross proceeds of 461.16.
Outset Medical insider plans Rule 144 stock sale. A holder of Outset Medical (symbol OM) common stock, identified as Leslie Trigg, filed notice to sell 11,794 shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 60,385.28. The filing states that 18,153,090 shares of common stock were outstanding. The shares to be sold come from 32,552 shares of common stock acquired on 01/17/2026 through settlement of vested restricted stock units as equity compensation for services rendered. In the past three months, the same seller reported two sales totaling 2,711 shares of common stock, generating combined gross proceeds of 11,878.25.
OM received a notice that insider John Brottem plans to sell 9,314 shares of its common stock through Morgan Stanley Smith Barney LLC on or about 01/20/2026 on the NASDAQ market. The filing lists an aggregate market value of $47,682.76 for these shares, compared with 18,153,090 shares of common stock outstanding.
The securities to be sold were acquired on 01/17/2026 through settlement of 17,997 vested restricted stock units as equity compensation for services rendered. The notice also reports that during the prior three months, Brottem sold 388 shares on 11/17/2025 for $1,784.80 and 244 shares on 01/07/2026 for $956.48. By signing, the seller represents they are not aware of undisclosed material adverse information about OM.
BML Investment Partners, L.P., a Delaware limited partnership, reported a significant ownership position in Outset Medical, Inc. common stock on a Schedule 13G. BML disclosed beneficial ownership of 1,705,876 shares of common stock, representing 9.4% of the outstanding class.
BML reported shared voting and dispositive power over all 1,705,876 shares, with no sole voting or dispositive authority. The filing is signed by Braden M. Leonard on behalf of BML Capital Management, LLC, the general partner of BML Investment Partners, L.P., and notes that Leonard is deemed an indirect owner of these shares. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Outset Medical, indicating a passive investment intent.
Outset Medical, Inc. director Karen Prange reported an equity grant in the form of restricted stock units. On January 9, 2026, she was awarded 18,667 RSUs, each representing a contingent right to receive one share of Outset Medical common stock at a price of $0.00 per unit.
The RSUs vest quarterly over three years, conditioned on her continued service with the company through each applicable vesting date. Following this grant, she beneficially owns 18,667 shares of common stock directly.
Outset Medical, Inc. director reports no beneficial ownership. Karen Prange, identified as a director of Outset Medical, Inc. (symbol OM), filed an initial statement of beneficial ownership of securities as of 01/09/2026. The filing states that no securities are beneficially owned, and both the non-derivative and derivative securities tables contain no holdings. The form is filed by a single reporting person and includes a power of attorney authorizing execution of the filing on her behalf.
Outset Medical, Inc. reported that it issued a press release with expected revenue for the fourth quarter and full year ended December 31, 2025, noting that this financial information is preliminary, unaudited and may change as closing and audit processes are completed. The company also furnished an updated investor presentation.
Board member Andrea Saia resigned effective January 9, 2026, and the company stated her departure was not due to any disagreement on operations, policies or practices. The Board appointed Karen Prange as a new independent director and Compensation Committee member, filling the vacancy as a class III director with a term running until the 2026 annual meeting. In connection with her appointment, Prange will receive an initial grant of 18,667 restricted stock units that vest quarterly over three years and an annual grant of 10,667 restricted stock units, subject to the company’s non‑employee director compensation policy.
Outset Medical executive Marc Nash reported a small, tax-related stock sale. On January 7, 2026, he sold 108 shares of Outset Medical common stock at $4.27 per share.
According to the footnote, the sale was required to cover tax withholding obligations tied to 289 shares underlying performance stock units that were earned based on performance criteria as of December 31, 2024 or January 6, 2025 and that vested and were released on January 6, 2025. The transaction was executed as a "sell to cover" and is described as not a discretionary trade by Nash.
After this sale, Nash directly beneficially owns 48,160 shares of Outset Medical common stock.